Literature DB >> 25339321

[Optimal treatment of adult Ph negative acute lymphoblastic leukemia].

Xingli Zhao1, Hui Wei1, Dong Lin1, Ying Wang1, Chunlin Zhou1, Bingcheng Liu1, Wei Li1, Kaiqi Liu1, Huijun Wang1, Chengwen Li1, Qinghua Li1, Benfa Gong1, Yuntao Liu1, Xiaoyuan Gong1, Yingchang Mi1, Jianxiang Wang1.   

Abstract

OBJECTIVE: To analyze the difference of safety and efficacy between the traditional and the pediatric inspired acute lymphoblastic leukemia (ALL) chemotherapy regimen, and to further observe whether patients in different age group will benefit from the two regimens.
METHODS: Adult de novo Ph negative ALL patients in our hospital from Jan 4, 2009 to Sep 4, 2013 were involved in this study and divided into 2 groups according to treatment regimens, the traditional regimen (regimen 1) and modified pediatric regimen (regimen 2) groups, respectively. The safety and the efficacy of all patients and different regimen groups were evaluated statistically.
RESULTS: All 144 patients received the induction therapy. The total complete remission (CR) rate was 95.8%, one course CR rate was 92.4%, and 5 year overall survival (OS) and progression free survival (RFS) were 59.0% and 48.6% respectively. The CR rate, 3 year OS and 3 year RFS between the two different regimens were 95.6% vs 96.1% (P = 0.783), 65.3% vs 63.4% (P = 0.885) and 56.0% vs 50.0% (P = 0.931), respectively. Further analysis stratified with age was also performed. For the patients treated with regimen 1, the 3 year OS and RFS between the two different age groups (14-30 years and 31-60 years) was 69.6% vs 54.7% (P = 0.042) and 56.5% vs 57.0% (P = 0.472). For the patients treated with regimen 2, the 3 year OS and RFS between the two different age groups (14-30 years and 31-60 years) was 65.7% vs 60.3% (P = 0.423) and 51.5% vs 46.6% (P = 0.655). No differences were found on the respiratory failure, cardiac dysfunction, fungal infection and intestinal obstruction between the two treatment regimen groups. The incidence of renal dysfunction for regimen 1 was lower than that of regimen 2 (P = 0.011). The incidence of bacteremia for regimen 1 was higher than that of regimen 2 (P = 0.000).
CONCLUSION: The two treatment regimens for adult Ph negative ALL patients were well tolerated and showed relative favorable CR rate and long term survival rate. The older patients (31-60 years) tended to benefit from the regiment 2 which was less intensive and consisted of more agents with low suppression to bone marrow.

Entities:  

Mesh:

Year:  2014        PMID: 25339321     DOI: 10.3760/cma.j.issn.0253-2727.2014.10.001

Source DB:  PubMed          Journal:  Zhonghua Xue Ye Xue Za Zhi        ISSN: 0253-2727


  4 in total

1.  Prognostic significance of copy number alterations detected by multi-link probe amplification of multiple genes in adult acute lymphoblastic leukemia.

Authors:  Qiuyun Fang; Tian Yuan; Yan Li; Juan Feng; Xiaoyuan Gong; Qinghua Li; Xingli Zhao; Kaiqi Liu; Kejing Tang; Zheng Tian; Qi Zhang; Ying Wang; Bingcheng Liu; Min Wang; Kun Ru; Jianxiang Wang; Yingchang Mi
Journal:  Oncol Lett       Date:  2018-02-07       Impact factor: 2.967

2.  [Screening of adult Ph-like acute lymphoblastic leukemia by multiplex real-time quantitative PCR].

Authors:  M Z Xu; Q Y Fang; X Y Gong; J Feng; Y J Jia; Q H Li; K Q Liu; X L Zhao; K Ru; Z Tian; K J Tang; M Wang; J X Wang; Y C Mi
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-11-14

3.  Gene Deletions and Prognostic Values in B-Linage Acute Lymphoblastic Leukemia.

Authors:  Qiuyun Fang; Yang Song; Xiaoyuan Gong; Jun Wang; Qinghua Li; Kaiqi Liu; Yahui Feng; Qishan Hao; Yan Li; Hui Wei; Guangji Zhang; Yuntao Liu; Benfa Gong; Ying Wang; Chunlin Zhou; Dong Lin; Bingcheng Liu; Shuning Wei; Runxia Gu; Yingchang Mi; Jianxiang Wang
Journal:  Front Oncol       Date:  2021-06-02       Impact factor: 6.244

4.  [Efficacy of Hyper-CVAD/MA and CHALL-01 regimens in the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia patients under 60 years old].

Authors:  A J Huang; L B Wang; J Du; G S Tang; H Cheng; S L Gong; L Gao; H Y Qiu; X Ni; J Chen; L Chen; W P Zhang; J M Wang; J M Yang; X X Hu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2019-08-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.